Altered Intercellular Communication

Cells coordinate tissue function through hormonal signaling, direct contact, and secreted vesicles carrying proteins, RNA, and other molecules. Aging disrupts this coordination in specific, measurable ways: senescent cells secrete a mix of inflammatory cytokines, chemokines, and proteases collectively called the SASP, which can spread senescence-like changes to neighboring healthy cells, a phenomenon called paracrine senescence [1]. This was one of the original nine hallmarks named in the 2013 López-Otín paper [1].

A 2023 review highlighted extracellular vesicles (small membrane-bound particles released by cells) as an underappreciated carrier of aging signals between tissues, showing that vesicles from aged donor cells can transfer senescence markers and inflammatory signaling to younger recipient cells in culture and in some mouse transfer experiments [2]. Endocrine signaling also shifts with age: declining growth hormone, sex hormones, and altered insulin/IGF-1 signaling change how tissues receive systemic cues, though hormone replacement to counter these shifts carries its own risk profile: the 2023 TRAVERSE trial found testosterone replacement noninferior to placebo for major cardiac events in hypogonadal men (7.0% vs 7.3%, HR 0.96), but with higher rates of atrial fibrillation (3.5% vs 2.4%) and acute kidney injury (2.3% vs 1.5%) [5].

What the evidence does not show: no human trial has directly targeted "intercellular communication" as a single mechanism, since it is really an umbrella covering several distinct signaling systems, each with different intervention profiles and risk trade-offs. Senolytic drugs that clear SASP-producing senescent cells are the most direct therapeutic approach under this hallmark, and a translational review of cellular senescence specifically flagged paracrine spread of senescence through secreted factors as the mechanistic reason senolytics could plausibly have effects beyond the tissue where cells are cleared [4]. As covered under senescence clearance, human RCT evidence for senolytics remains limited to small trials with surrogate endpoints, not large mortality or disability outcome trials.

Blueprint tracks several downstream markers of altered communication indirectly, including inflammatory markers (hs-CRP) and hormone panels, as part of Bryan Johnson's broader biomarker suite, though no single Blueprint metric isolates intercellular communication as its own construct [3].

Critics note that "altered intercellular communication" is one of the vaguer hallmarks precisely because it aggregates hormonal, paracrine, and vesicle-based signaling into one category, making it harder to design a single targeted trial compared to more mechanistically narrow hallmarks like telomere attrition or senescence [1]. The 2023 hallmarks-of-aging update retained it as a distinct category despite this breadth, arguing that the shared theme of cross-tissue signal spread justified keeping it separate from cell-intrinsic hallmarks like genomic instability [6]. The plain takeaway: cell-to-cell signaling genuinely changes with age in ways that spread dysfunction across tissues, but the science is still building the tools to intervene on this broad category as a whole rather than one signaling pathway at a time.